Prodrugs of active agents

1. A compound of structural Formula:

or salts thereof wherein:

X is an opioid, an amphetamine, or a phenidate and X is covalently bonded to —(CR 2 R 3 )—via an amine, a phenol, a carboxylic acid or a thiol;

R 2 and R 3 are independently hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroarylalkyl;

R k 16 are each independently selected from the group consisting of one or more of —F, —Cl, —Br, —I, —R 4 , —O − , —OR 4 , —SR 4 , —S − , —NR 4 R 5 , —CF 3 , —CN, —OCN, —SCN, —NO, —NO 2 , —N 3 , —S(O) 2 O − , —S(O) 2 OH, —S(O) 2 R 4 , —OS(O 2 )O − , —OS(O) 2 R 4 , —P(O)(O − ) 2 , —P(O)(OR 4 )(O − ), —OP(O)(OR 4 )(OR 5 ), —C(O)R 4 , —C(S)R 4 , —C(O)OR 4 , —C(O)NR 4 R 5 , —C(O)O − , —C(S)OR 4 , —NR 6 C(O)NR 4 R 5 , —NR 6 C(S)NR 4 R 5 , —NR 7 C(NR 6 )NR 5 R 4 and —C(NR 6 )NR 5 R 4 , and k is 0, 1, 2, 3, or 4;

R 4 , R 5 , R 6 and R 7 are independently hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl, or optionally R 4 and R 5 together with the nitrogen atom to which they are bonded form a cycloheteroalkyl or substituted cycloheteroalkyl ring;

R 8 is hydrogen or methyl;

R 12 is an amino acid side chain;

each U is independently —NR 13 —, —O—or —S—;

each R 13 is independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroarylalkyl or optionally, R 13 and R 14 together with the atoms to which they are bonded form a cycloheteroalkyl or substituted cycloheteroalkyl ring; and

R 14 is hydrogen, acyl, or —CO 2 —t—butyl; and

o is an integer from 1 to 5.

2. The compound of claim 1 in which X is an opioid.

3. The compound of claim 1 in which X is morphine, codeine, diacetylmorphine, hydrocodone, hydromorphone, levorphanol, oxycodone, oxymorphone, naltrexone, nalbuphine, butorphanol, nalorphine, alfentanil, buprenorphine, carfentanil, dihydrocodeine, dihydroetorphine, diprenorphine, etorphine, fentanyl, levomethadyl acetate hydrochloride, lofentanil, meperidine, methadone, morphine, naloxone, methyl naltrexone, beta-hydroxy 3-methylfentanyl, N-methylnaltrexone, normorphine, propoxyphene, remifentanil, sufentanil, tilidine, thebaine, nalbuphine, nalmefene, neopine, penomorphone or tramadol.

4. The compound of claim 1 in which X is morphine, codeine, diacetylmorphine, etorphine, hydrocodone, hydromorphone, levorphanol, oxycodone, oxymorphone, naltrexone, nalbuphine, butorphanol, or nalorphine.

5. The compound of claim 1 in which X is oxycodone, hydrocodone, oxymorphone, hydromorphone or codeine.

6. The compound of claim 1 of structural Formula (III):

wherein R 8 is hydrogen or methyl, R 12 is an amino acid side chain, R 14 is hydrogen, acyl, or —CO 2 -t-butyl, o is an integer from 1 to 5, R k 16 are each independently selected from the group consisting of one or more of —F, —Cl, —Br, —I, —R 4 , —O − , —OR 4 , —SR 4 , —S − , —NR 4 R 5 , —CF 3 , —CN, —OCN, —SCN, —NO, —NO 2 , —N 3 , —S(O) 2 O − , —S(O) 2 OH, —S(O) 2 R 4 , —OS(O 2 )O − , —OS(O) 2 R 4 , —P(O)(O − ) 2 , —P(O)(OR 4 )(O − ), —OP(O)(OR 4 )(OR 5 ), —C(O)R 4 , —C(S)R 4 , —C(O)OR 4 , —C(O)NR 4 R 5 , —C(O)O − , —C(S)OR 4 , —NR 6 C(O)NR 4 R 5 , —NR 6 C(S)NR 4 R 5 , —NR 7 C(NR 6 )NR 5 R 4 and —C(NR 6 )NR 5 R 4 , and k is 0, 1, 2, 3, or 4.

7. The compound of claim 1 of structural Formula (IV):

wherein R 8 is hydrogen or methyl, R 12 is an amino acid side chain, R 14 is hydrogen, acyl, or —CO 2 -t-butyl, o is an integer from 1 to 5, R k 16 are each independently selected from the group consisting of one or more of —F, —Cl, —Br, —I, —R 4 , —O − , —OR 4 , —SR 4 , —S − , —NR 4 R 5 , —CF 3 , —CN, —OCN, —SCN, —NO, —NO 2 , —N 3 , —S(O) 2 O − , —S(O) 2 OH, —S(O) 2 R 4 , —OS(O 2 )O − , —OS(O) 2 R 4 , —P(O)(O − ) 2 , —P(O)(OR 4 )(O − ), —OP(O)(OR 4 )(OR 5 ), —C(O)R 4 , —C(S)R 4 , —C(O)OR 4 , —C(O)NR 4 R 5 , —C(O)O − , —C(S)OR 4 , —NR 6 C(O)NR 4 R 5 , —NR 6 C(S)NR 4 R 5 , —NR 7 C(NR 6 )NR 5 R 4 and —C(NR 6 )NR 5 R 4 , and k is 0, 1, 2, 3, or 4.

8. The compound of claim 1 of structural Formula (V):

wherein R 8 is hydrogen or methyl, R 12 is an amino acid side chain, R 14 is hydrogen, acyl, or —CO 2 -t-butyl, o is an integer from 1 to 5, R k 16 are each independently selected from the group consisting of one or more of —F, —Cl, —Br, —I, —R 4 , —O − , —OR 4 , —SR 4 , —S − , —NR 4 R 5 , —CF 3 , —CN, —OCN, —SCN, —NO, —NO 2 , —N 3 , —S(O) 2 O − , —S(O) 2 OH, —S(O) 2 R 4 , —OS(O 2 )O − , —OS(O) 2 R 4 , —P(O)(O − ) 2 , —P(O)(OR 4 )(O − ), —OP(O)(OR 4 )(OR 5 ), —C(O)R 4 , —C(S)R 4 , —C(O)OR 4 , —C(O)NR 4 R 5 , —C(O)O − , —C(S)OR 4 , —NR 6 C(O)NR 4 R 5 , —NR 6 C(S)NR 4 R 5 , —NR 7 C(NR 6 )NR 5 R 4 and —C(NR 6 )NR 5 R 4 , and k is 0, 1, 2, 3, or 4.

9. The compound of claim 1 of structural Formula (VI):

wherein R 8 is hydrogen or methyl, R 12 is an amino acid side chain, R 14 is hydrogen, acyl, or —CO 2 -t-butyl, o is an integer from 1 to 5, R k 16 are each independently selected from the group consisting of one or more of —F, —Cl, —Br, —I, —R 4 , —O − , —OR 4 , —SR 4 , —S − , —NR 4 R 5 , —CF 3 , —CN, —OCN, —SCN, —NO, —NO 2 , —N 3 , —S(O) 2 O − , —S(O) 2 OH, —S(O) 2 R 4 , —OS(O 2 )O − , —OS(O) 2 R 4 , —P(O)(O − ) 2 , —P(O)(OR 4 )(O − ), —OP(O)(OR 4 )(OR 5 ), —C(O)R 4 , —C(S)R 4 , —C(O)OR 4 , —C(O)NR 4 R 5 , —C(O)O − , —C(S)OR 4 , —NR 6 C(O)NR 4 R 5 , —NR 6 C(S)NR 4 R 5 , —NR 7 C(NR 6 )NR 5 R 4 and —C(NR 6 )NR 5 R 4 , and k is 0, 1, 2, 3, or 4.

10. The compound of claim 1 of structural Formula (VII):

wherein R 8 is hydrogen or methyl, R 12 is an amino acid side chain, R 14 is hydrogen, acyl, or —CO 2 -t-butyl, o is an integer from 1 to 5, R k 16 are each independently selected from the group consisting of one or more of —F, —Cl, —Br, —I, —R 4 , —O − , —OR 4 , —SR 4 , —S − , —NR 4 R 5 , —CF 3 , —CN, —OCN, —SCN, —NO, —NO 2 , —N 3 , —S(O) 2 O − , —S(O) 2 OH, —S(O) 2 R 4 , —OS(O 2 )O − , —OS(O) 2 R 4 , —P(O)(O − ) 2 , —P(O)(OR 4 )(O − ), —OP(O)(OR 4 )(OR 5 ), —C(O)R 4 , —C(S)R 4 , —C(O)OR 4 , —C(O)NR 4 R 5 , —C(O)O − , —C(S)OR 4 , —NR 6 C(O)NR 4 R 5 , —NR 6 C(S)NR 4 R 5 , —NR 7 C(NR 6 )NR 5 R 4 and —C(NR 6 )NR 5 R 4 , and k is 0, 1, 2, 3, or 4.

11. The compound of claim 1 of structural Formula (VIII):

wherein R 8 is hydrogen or methyl, R 12 is an amino acid side chain, R 14 is hydrogen, acyl, or —CO 2 -t-butyl, o is an integer from 1 to 5, R k 16 are each independently selected from the group consisting of one or more of —F, —Cl, —Br, —I, —R 4 , —O − , —OR 4 , —SR 4 , —S − , —NR 4 R 5 , —CF 3 , —CN, —OCN, —SCN, —NO, —NO 2 , —N 3 , —S(O) 2 O − , —S(O) 2 OH, —S(O) 2 R 4 , —OS(O 2 )O − , —OS(O) 2 R 4 , —P(O)(O − ) 2 , —P(O)(OR 4 )(O − ), —OP(O)(OR 4 )(OR 5 ), —C(O)R 4 , —C(S)R 4 , —C(O)OR 4 , —C(O)NR 4 R 5 , —C(O)O − , —C(S)OR 4 , —NR 6 C(O)NR 4 R 5 , —NR 6 C(S)NR 4 R 5 , —NR 7 C(NR 6 )NR 5 R 4 and —C(NR 6 )NR 5 R 4 , and k is 0, 1, 2, 3, or 4.

12. The compound of claim 1 of structural Formula (IX):

wherein R 8 is hydrogen or methyl, R 12 is an amino acid side chain, R 14 is hydrogen, acyl, or —CO 2 -t-butyl, o is an integer from 1 to 5, R k 16 are each independently selected from the group consisting of one or more of —F, —Cl, —Br, —I, —R 4 , —O − , —OR 4 , —SR 4 , —S − , —NR 4 R 5 , —CF 3 , —CN, —OCN, —SCN, —NO, —NO 2 , —N 3 , —S(O) 2 O − , —S(O) 2 OH, —S(O) 2 R 4 , —OS(O 2 )O − , —OS(O) 2 R 4 , —P(O)(O − ) 2 , —P(O)(OR 4 )(O − ), —OP(O)(OR 4 )(OR 5 ), —C(O)R 4 , —C(S)R 4 , —C(O)OR 4 , —C(O)NR 4 R 5 , —C(O)O − , —C(S)OR 4 , —NR 6 C(O)NR 4 R 5 , —NR 6 C(S)NR 4 R 5 , —NR 7 C(NR 6 )NR 5 R 4 and —C(NR 6 )NR 5 R 4 , and k is 0, 1, 2, 3, or 4.

13. The compound of claim 1 of structural Formula (X):

wherein R 8 is hydrogen or methyl, R 12 is an amino acid side chain, R 14 is hydrogen, acyl, or —CO 2 -t-butyl, o is an integer from 1 to 5, R k 16 are each independently selected from the group consisting of one or more of —F, —Cl, —Br, —I, —R 4 , —O − , —OR 4 , —SR 4 , —S − , —NR 4 R 5 , —CF 3 , —CN, —OCN, —SCN, —NO, —NO 2 , —N 3 , —S(O) 2 O − , —S(O) 2 OH, —S(O) 2 R 4 , —OS(O 2 )O − , —OS(O) 2 R 4 , —P(O)(O − ) 2 , —P(O)(OR 4 )(O − ), —OP(O)(OR 4 )(OR 5 ), —C(O)R 4 , —C(S)R 4 , —C(O)OR 4 , —C(O)NR 4 R 5 , —C(O)O − , —C(S)OR 4 , —NR 6 C(O)NR 4 R 5 , —NR 6 C(S)NR 4 R 5 , —NR 7 C(NR 6 )NR 5 R 4 and —C(NR 6 )NR 5 R 4 , and k is 0, 1, 2, 3, or 4.

14. The compound of claim 1 of structural Formula (XI):

wherein R 8 is hydrogen or methyl, R 12 is an amino acid side chain, R 14 is hydrogen, acyl, or —CO 2 -t-butyl, o is an integer from 1 to 5, R k 16 are each independently selected from the group consisting of one or more of —F, —Cl, —Br, —I, —R 4 , —O − , —OR 4 , —SR 4 , —S − , —NR 4 R 5 , —CF 3 , —CN, —OCN, —SCN, —NO, —NO 2 , —N 3 , —S(O) 2 O − , —S(O) 2 OH, —S(O) 2 R 4 , —OS(O 2 )O − , —OS(O) 2 R 4 , —P(O)(O − ) 2 , —P(O)(OR 4 )(O − ), —OP(O)(OR 4 )(OR 5 ), —C(O)R 4 , —C(S)R 4 , —C(O)OR 4 , —C(O)NR 4 R 5 , —C(O)O − , —C(S)OR 4 , —NR 6 C(O)NR 4 R 5 , —NR 6 C(S)NR 4 R 5 , —NR 7 C(NR 6 )NR 5 R 4 and —C(NR 6 )NR 5 R 4 , and k is 0, 1, 2, 3, or 4.

15. The compound of claim 1 of structural Formula (XII):

wherein R 8 is hydrogen or methyl, R 12 is an amino acid side chain, R 14 is hydrogen, acyl, or —CO 2 -t-butyl, o is an integer from 1 to 5, R k 16 are each independently selected from the group consisting of one or more of —F, —Cl, —Br, —I, —R 4 , —O − , —OR 4 , —SR 4 , —S − , —NR 4 R 5 , —CF 3 , —CN, —OCN, —SCN, —NO, —NO 2 , —N 3 , —S(O) 2 O − , —S(O) 2 OH, —S(O) 2 R 4 , —OS(O 2 )O − , —OS(O) 2 R 4 , —P(O)(O − ) 2 , —P(O)(OR 4 )(O − ), —OP(O)(OR 4 )(OR 5 ), —C(O)R 4 , —C(S)R 4 , —C(O)OR 4 , —C(O)NR 4 R 5 , —C(O)O − , —C(S)OR 4 , —NR 6 C(O)NR 4 R 5 , —NR 6 C(S)NR 4 R 5 , —NR 7 C(NR 6 )NR 5 R 4 and —C(NR 6 )NR 5 R 4 , and k is 0, 1, 2, 3, or 4.

16. The compound of claim 1 in which X is an amphetamine or a methyphenidate.

17. The compound of claim 1 in which X is selected from the group consisting of amphetamine, dextroamphetamine, methamphetamine, p-methoxy amphetamine, methylenedioxyamphetamine, 2,5-dimethoxy-4-methylamphetamine, 2,4,5-trimethoxyamphetamine, 3,4-methylenedioxyamphetamine, methylphenidate, and D-methylphenidate.

18. The compound of claim 1 in which X is an opioid;

R 2 and R 3 are independently hydrogen, alkyl, aryl or arylalkyl; and

R 12 is methyl, benzyl, —CH 2 CO 2 H, —CH 2 (CH 2 ) 3 NH 2 or —CH 2 CH 2 CH 2 NHC(NH)NH 2 and

R 13 is hydrogen.

19. The compound of claim 18 in which o is 2, the R 12 closest to the opioid is —CH 2 (CH 2 ) 3 NH 2 or —CH 2 CH 2 CH 2 NHC(NH)NH 2 , any other R 12 is hydrogen, methyl, isopropyl, isobutyl, sec-butyl, t-butyl, cyclopentyl, cyclohexyl, —CH 2 OH, —CH(OH)CH 3 , —CH 2 CO 2 H, —CH 2 CH 2 CO 2 H, —CH 2 CONH 2 , —CH 2 CH 2 CONH 2 , —CH 2 CH 2 SCH 3 , —CH 2 SH, —CH 2 (CH 2 ) 3 NH 2 , —CH 2 CH 2 CH 2 NHC(NH)NH 2 , phenyl, benzyl, homobenzyl, 4-hydroxybenzyl, 4-bromobenzyl, 4-imidazolylmethyl or 3indolylmethyl, U is NR 13 and each R 13 is hydrogen.

20. A method of reducing or deterring abuse of a drug, comprising providing to a patient a therapeutically effective amount of the compound of claim 1 .

21. The compound of claim 1 of structural Formula:

wherein R 8 is hydrogen or methyl, R 12 is an amino acid side chain, R 14 is hydrogen, acyl, or —CO 2 -t-butyl, o is an integer from 1 to 5, R k 16 are each independently selected from the group consisting of one or more of —F, —Cl, —Br, —I, —R 4 , —O − , —OR 4 , —SR 4 , —S − , —NR 4 R 5 , —CF 3 , —CN, —OCN, —SCN, —NO, —NO 2 , —N 3 , —S(O) 2 O − , —S(O) 2 OH, —S(O) 2 R 4 , —OS(O 2 )O − , —OS(O) 2 R 4 , —P(O)(O − ) 2 , —P(O)(OR 4 )(O − ), —OP(O)(OR 4 )(OR 5 ), —C(O)R 4 , —C(S)R 4 , —C(O)OR 4 , —C(O)NR 4 R 5 , —C(O)O − , —C(S)OR 4 , —NR 6 C(O)NR 4 R 5 , —NR 6 C(S)NR 4 R 5 , —NR 7 C(NR 6 )NR 5 R 4 and —C(NR 6 )NR 5 R 4 , and k is 0, 1, 2, 3, or 4.

22. The compound of claim 1 of structural Formula:

wherein R 8 is hydrogen or methyl, R 12 is an amino acid side chain, R 14 is hydrogen, acyl, or —CO 2 -t-butyl, o is an integer from 1 to 5, R k 16 are each independently selected from the group consisting of one or more of —F, —Cl, —Br, —I, —R 4 , —O − , —OR 4 , —SR 4 , —S − , —NR 4 R 5 , —CF 3 , —CN, —OCN, —SCN, —NO, —NO 2 , —N 3 , —S(O) 2 O − , —S(O) 2 OH, —S(O) 2 R 4 , —OS(O 2 )O − , —OS(O) 2 R 4 , —P(O)(O − ) 2 , —P(O)(OR 4 )(O − ), —OP(O)(OR 4 )(OR 5 ), —C(O)R 4 , —C(S)R 4 , —C(O)OR 4 , —C(O)NR 4 R 5 , —C(O)O − , —C(S)OR 4 , —NR 6 C(O)NR 4 R 5 , —NR 6 C(S)NR 4 R 5 , —NR 7 C(NR 6 )NR 5 R 4 and —C(NR 6 )NR 5 R 4 , and k is 0, 1, 2, 3, or 4.

23. The compound of claim 1 of structural Formula:

wherein R 8 is hydrogen or methyl, R 12 is an amino acid side chain, R 14 is hydrogen, acyl, or —CO 2 -t-butyl, o is an integer from 1 to 5, R k 16 are each independently selected from the group consisting of one or more of —F, —Cl, —Br, —I, —R 4 , —O − , —OR 4 , —SR 4 , —S − , —NR 4 R 5 , —CF 3 , —CN, —OCN, —SCN, —NO, —NO 2 , —N 3 , —S(O) 2 O − , —S(O) 2 OH, —S(O) 2 R 4 , —OS(O 2 )O − , —OS(O) 2 R 4 , —P(O)(O − ) 2 , —P(O)(OR 4 )(O − ), —OP(O)(OR 4 )(OR 5 ), —C(O)R 4 , —C(S)R 4 , —C(O)OR 4 , —C(O)NR 4 R 5 , —C(O)O − , —C(S)OR 4 , —NR 6 C(O)NR 4 R 5 , —NR 6 C(S)NR 4 R 5 , —NR 7 C(NR 6 )NR 5 R 4 and —C(NR 6 )NR 5 R 4 , and k is 0, 1, 2, 3, or 4.

24. The compound of claim 1 of structural Formula:

wherein R 8 is hydrogen or methyl, R 12 is an amino acid side chain, R 14 is hydrogen, acyl, or —CO 2 -t-butyl, o is an integer from 1 to 5, R k 16 are each independently selected from the group consisting of one or more of —F, —Cl, —Br, —I, —R 4 , —O − , —OR 4 , —SR 4 , —S − , —NR 4 R 5 , —CF 3 , —CN, —OCN, —SCN, —NO, —NO 2 , —N 3 , —S(O) 2 O − , —S(O) 2 OH, —S(O) 2 R 4 , —OS(O 2 )O − , —OS(O) 2 R 4 , —P(O)(O − ) 2 , —P(O)(OR 4 )(O − ), —OP(O)(OR 4 )(OR 5 ), —C(O)R 4 , —C(S)R 4 , —C(O)OR 4 , —C(O)NR 4 R 5 , —C(O)O − , —C(S)OR 4 , —NR 6 C(O)NR 4 R 5 , —NR 6 C(S)NR 4 R 5 , —NR 7 C(NR 6 )NR 5 R 4 and —C(NR 6 )NR 5 R 4 , and k is 0, 1, 2, 3, or 4.

25. A method of treating attention deficit hyperactivity disorder (ADHD), depression, obesity or narcolepsy in a patient comprising administering to a patient in need of such treatment a therapeutically effective amount of the compound of claim 1 wherein X is an amphetamine or a methylphenidate.

26. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable vehicle.

27. A method of treating pain in a patient comprising administering to a patient in need of such treatment a therapeutically effective amount of the compound of claim 1 , wherein X is an opioid.

28. The method of claim 27 in which the pain is acute pain, chronic pain, neuropathic pain, arthritic pain, osteoarthritic pain, rheumatoid arthritic pain, musculoskeletal pain, myofascial pain, cancer pain, visceral pain, diabetic pain, muscular pain, post-herpetic neuralgic pain, chronic pelvic pain, endometriosis pain or pelvic inflammatory pain.